Myeloma Paper of the Day, July 19th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Once-weekly KRd56 appears similar to twice-weekly KRd27 for patients with relapsed/refractory myeloma, with ORR 82.5% vs. 86.3%, comparable PFS, and similar safety profiles while enhancing convenience.”
Source: Robert Orlowski/X
Authors: Meletios-Athanasios A. DimopoulosDaniel CoriuSosana DelimpasiIvan SpickaTerry E UpchurchBelle FangRakhshandra TalpurEdward Anthony Faber JrMeral Beksac, and Xavier Leleu.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
